The Hidden Muscle Loss Risk on Ozempic, Wegovy & Zepbound
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
GLP-1 medications like Ozempic, Wegovy, and Zepbound are powerful tools for weight loss — but many patients don’t realize they can also lose muscle if nutrition and training aren’t optimized.
In this video, Dr. Mohammed Paika (board-certified in Internal Medicine & Obesity Medicine) explains how to lose fat while protecting metabolism, strength, and long-term results.
You’ll learn the most common causes of muscle loss on GLP-1s, ideal protein targets, and why strength training is the key signal your body needs during weight loss.
If you want sustainable fat loss — not just weight loss — this is critical.
⚕️ Medical & Educational Disclaimer
The Dr. Paika Podcast and all related content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information shared is not intended as medical advice and should not be used as a substitute for consultation with your personal physician or qualified healthcare professional.
Listening to this podcast does not create a doctor-patient relationship between you and Dr. Paika.
Health, nutrition, exercise, medication, and weight-management topics discussed may not be appropriate for all individuals. Always consult your own healthcare provider before starting or changing any medication, diet, exercise program, or weight-loss plan, including GLP-1 therapies such as Wegovy, Ozempic, Zepbound, Mounjaro, or similar medications.
Exercise and lifestyle changes carry inherent risks. By choosing to apply any information from this podcast, you accept full responsibility for your health decisions and outcomes.
Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from the use or application of information presented in this podcast.